West Pharmaceutical Services (WST) remains a focal topic amidst some mixed performance. Key share acquisition by several organisations including
Swedbank AB and
Susquehanna Fundamental Investments LLC indicates a robust market interest. Despite this,
Q3 2024 earnings are projected to decline.
Second-quarter 2024 results were announced, but the full-year sales and profit forecast have been lowered due to subdued demand. Despite some financial vagueness, the firm secured the
Heart of Pharma Award in 2024 at the
CPHI Pharma Awards, showing industry recognition. In a surprising move,
CTO Silji Abraham resigned.
EPS for Q2 2024 was disappointing, and lowered demand led to slashed 2024 forecasts. On a positive note, the company has received
FDA 510(k) clearance for their product
Vial2Bag Advanced® 13mm Admixture device. Intriguingly, West's CEO sold over $24m in company stock.
West, in collaboration with
Corning, has made significant strides in pharmaceutical injectable drug delivery. Also noteworthy is their inclusion in the
S&P 500 Index and a meaningful financial commitment to expand their facilities in
Kinston.
West Pharmaceutical Services WST News Analytics from Fri, 15 Jul 2016 08:25:28 GMT to Sat, 19 Oct 2024 07:50:54 GMT -
Rating -2
- Innovation 5
- Information 7
- Rumor -3
